Outlook Therapeutics · ONS-5010 · Dec 2025 – Jun 2026
How did evidence the FDA said did not alter its conclusion come to establish substantial evidence?
In December 2025 the FDA's letter found the added mechanistic and natural history data did not alter its conclusion. In May 2026, on appeal, the Office of New Drugs found that NORSE TWO with NORSE EIGHT, natural history and mechanistic data established substantial evidence. Both accounts are Outlook's.
EphemerisX Research · Published · 5 source documents · 1 min read
Short answer
On appeal. By Outlook's account, the FDA's December 2025 letter found that the added mechanistic and natural history data did not alter its conclusion. After a Type A meeting with the Division of Ophthalmology and the Office of Specialty Medicine, the company took the question to the Office of New Drugs, which in May 2026 found NORSE TWO together with NORSE EIGHT, natural history and mechanistic and pharmacodynamic data to be substantial evidence of effectiveness.
What the evidence shows
December 2025, as the company reported the letter: the additional mechanistic and natural history data information provided in the BLA resubmission does not alter the previous review conclusion that while the one adequate and well-controlled study demonstrated efficacy
8-K · Jan 2, 2026, with confirmatory evidence of efficacy
8-K · Jan 2, 2026 again recommended.
February 2026, the company's description of what it had submitted: a comprehensive package of confirmatory evidence, including mechanistic and pharmacodynamic data demonstrating VEGF inhibition and natural history data
8-K · Feb 11, 2026.
The April 21 release describes the dispute resolution meeting with the Office of New Drugs at the U.S. Food and Drug Administration (FDA)
8-K · Apr 21, 2026 as a follow-up to its recent Type A meeting with the Division of Ophthalmology and Office of Specialty Medicine
8-K · Apr 21, 2026.
May 2026, the company's account of the decision: OND determined that the results of the NORSE TWO trial, together with confirmatory evidence including NORSE EIGHT, natural history, and mechanistic and pharmacodynamic data, establish substantial evidence of effectiveness for LYTENAVA™ for the treatment of nAMD
8-K · May 26, 2026. In June it added: therefore additional trials are not required
8-K · Jun 1, 2026.
Not in this record: the Office of New Drugs' decision itself, or the minutes of the March 2026 Type A meeting. Both accounts above come from Outlook's filings; the FDA's own statement of the December deficiency is on a page without a text layer.
Follow the thread
- What changed between the FDA's August and December 2025 letters?Mechanistic and natural history data “does not alter”
- What happened after the FDA's December 2025 letter?From the division to the Office of New Drugs
- How did Outlook's description of NORSE EIGHT change?NORSE EIGHT as confirmatory evidence
- Why do Outlook's filings give different dates for the FDA's letters?The June 2026 release
This investigation connects to
- How did two programs move forward after repeat FDA letters without running a new trial?Cross-investigation · Comparable evidence · with Replimune
- What is a Class 1 or Class 2 resubmission, and how did each play out in these records?Cross-investigation · Regulatory pathway · with Aldeyra Therapeutics, CorMedix, Replimune
- When is one trial enough? How the FDA weighed the evidence in three programsCross-investigation · Comparable evidence · with Aldeyra Therapeutics, Replimune
The documents, by date
The passages quoted
Outlook Therapeutics Form 8-K, filed January 2, 2026
In the CRL, the FDA noted that the additional mechanistic and natural history data information provided in the BLA resubmission does not alter the previous review conclusion that while the one adequate and well-controlled study demonstrated efficacy, the FDA has again recommended that confirmatory evidence of efficacy be submitted to support the application, however the FDA has not indicated what type of confirmatory evidence would be acceptable.Open at the source →
Outlook Therapeutics Form 8-K, filed February 11, 2026
In addition to NORSE TWO and NORSE EIGHT, Outlook Therapeutics submitted a comprehensive package of confirmatory evidence, including mechanistic and pharmacodynamic data demonstrating VEGF inhibition and natural history data showing that the observed improvements with ONS-5010 represent a clear departure from the expected progression of untreated wet AMD.Open at the source →
Outlook Therapeutics Form 8-K, filed April 21, 2026
today announced that it has completed its Federal Dispute Resolution meeting w ith the Office of New Drugs at the U.S. Food and Drug Administration (FDA). The meeting was conducted as part of the Company’s ongoing efforts to seek alignment with the FDA regarding the regulatory pathway for ONS-5010 / LYTENAVA™ (bevacizumab-vikg) and as a follow-up to its recent Type A meeting with the Division of Ophthalmology and Office of Specialty Medicine regarding the December 30, 2025 Complete Response Letter (CRL) for the Biologics License Application (BLA) for ONS-5010/LYTENAVA™ for the treatment of neovascular age-related macular degenerationOpen at the source →
Outlook Therapeutics Form 8-K, filed May 26, 2026
In its formal response, OND determined that the results of the NORSE TWO trial, together with confirmatory evidence including NORSE EIGHT, natural history, and mechanistic and pharmacodynamic data, establish substantial evidence of effectiveness for LYTENAVA™ for the treatment of nAMD. The response directs the Division and OSM to work with Outlook Therapeutics to reach an agreement on final labeling. As indicated in the formal decision, it is anticipated that this will be a Class 1 resubmission with a PDUFA date and decision expected within 60 days of FDA’s receipt of the resubmission.Open at the source →
Outlook Therapeutics Form 8-K, filed June 1, 2026
As previously announced, Outlook Therapeutics successfully appealed the December 2026 Complete Response Letter (CRL) related to the ONS-5010 Biologics License Application reviewed by the FDA. In their decision, the FDA Office of New Drugs concluded that substantial evidence of effectiveness has been established for LYTENAVA™ for the treatment of neovascular age-related macular degeneration (nAMD), therefore additional trials are not required.Open at the source →